JERUSALEM, September 20, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that management will participate in the Ladenburg Thalmann 2017 Healthcare Conference to be held September 26, 2017 at the Sofitel Hotel in New York City.

JERUSALEM, September 8, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that management will participate in the 19th Annual Rodman & Renshaw Global Investment Conference to be held September 10-12, 2017 at the Lotte New York Palace Hotel in New York City.

JERUSALEM, September 1, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that management will participate in BioCentury's 24th Annual NewsMakers in the Biotech Industry Conference to be held on September 8, 2017 at the Millennium Broadway Hotel & Conference Center

JERUSALEM, August 21, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the closing of its previously announced offering of approximately 12.2 million of its ordinary shares, at a public offering price of $4.70 per ordinary share, which included a full exercise by the

JERUSALEM, August 16, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the pricing of an underwritten public offering of approximately 10.6 million of its ordinary shares at a public offering price of $4.70 per ordinary share.

JERUSALEM, Aug. 9, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC) (TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ (AP) platform technology, today reported financial results for the six months ended June 30, 2017.

JERUSALEM, July 27, 2017 /PRNewswire/ --  Intec Pharma Ltd. (Nasdaq, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ (AP) platform technology, announces the promotion of Nadav Navon, Ph.D., Executive Vice

JERUSALEM, July 19, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ, TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that the Patent Registry Intellectual Property Department of Hong Kong has

JERUSALEM, July 19, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ, TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill [ TM ]  platform technology, announces that the Patent Registry Intellectual Property Department of Hong

JERUSALEM, July 10, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces the appointment of Jeffrey A.